HLA-A*02:01-restricted T-cell receptor program is designed to recognize the HPV16 E7 oncoprotein through a defined viral peptide-HLA complex, expanding the company’s precision immuno-oncology pipeline for HPV-driven solid tumors
Cellantra, an in vivo gene therapy and next-generation immuno-oncology biotechnology company, today announced the discovery and invention of a novel T-cell receptor (TCR) candidate designed to recognize the HPV16 E7 oncoprotein in the context of HLA-A*02:01.
The proprietary receptor is being developed for TCR-engineered T-cell (TCR-T) therapy against HPV16-positive epithelial cancers. The program is directed toward the established HPV16 E7 11-19 peptide-HLA-A*02:01 target class, while the sequence, molecular configuration and performance characteristics of Cellantra’s lead receptor remain proprietary pending further validation and intellectual-property development.
HPV16 E7 is a virally encoded intracellular oncoprotein that is maintained in HPV-driven malignant cells and is not encoded by the normal human genome. TCR-based therapies can access this target because intracellular E7 protein is processed into short peptides that can be displayed by HLA molecules on the tumor-cell surface.
A New TCR Candidate Built Around a Clinically Validated Viral Neoantigen
Cellantra developed the HPV16 E7 program through its integrated TCR discovery, computational immunology, peptide-HLA modeling, structural evaluation and protein-engineering platform.
The lead candidate is designed to combine strong recognition of the E7 peptide-HLA-A*02:01 complex with strict dependence on the viral peptide sequence and the intended HLA restriction.
The candidate has advanced through the company’s discovery and molecular-prioritization stage. Cellantra is now advancing experimental studies designed to confirm functional avidity, tumor-cell recognition, antigen-density sensitivity, HLA dependence, peptide cross-reactivity and broader translational safety before determining readiness for formal preclinical development.
No clinical potency or therapeutic efficacy is claimed for the company’s candidate at this stage.
The HPV16 E7 TCR-T program is being developed around several core objectives:
- selective recognition of the HPV16 E7-derived peptide presented by HLA-A*02:01;
- strong T-cell activation and tumor-cell recognition at disease-relevant target density;
- minimal recognition of unrelated human peptide-HLA complexes and HLA-A*02:01-positive normal-cell contexts;
- systematic evaluation of sequence-related viral and human peptides, molecular mimics and potential off-target interactions;
- functional compatibility with optimized engineered T-cell architectures; and
- compatibility with future cellular-control modules and targeted in vivo immune-cell programming technologies.
Targeting a Viral Oncoprotein That Helps Sustain HPV-Driven Cancer
Persistent expression of the HPV E6 and E7 oncogenes is a defining biological feature of HPV-driven carcinogenesis. Because E7 is intracellular, it is generally inaccessible to conventional antibody- or CAR-based recognition; peptide processing and HLA presentation can instead expose an E7-derived molecular signature to TCR-expressing T cells.
For HLA-A*02:01-positive patients with HPV16-positive tumors, this creates a genetically and virologically defined therapeutic population.
Prior academic and clinical studies have demonstrated that T cells engineered with an HPV16 E7-specific, HLA-A*02:01-restricted TCR can recognize HPV16-positive tumor cells, and clinical studies have reported tumor regression in patients with metastatic HPV-associated epithelial cancers. Cellantra’s receptor is an independent discovery program and is not presented as equivalent to previously reported clinical TCRs.
“HPV16 E7 is a compelling TCR target because it is a virally encoded cancer driver with a defined peptide-HLA presentation mechanism and substantial biological precedent,” the company said. “Our objective is to invent a receptor that combines precise E7/HLA-A02:01 recognition with the specificity, functional strength and translational safety required for a next-generation TCR-T program. We are treating potency and safety as linked engineering problems rather than optimizing either in isolation.”*
Potential Application Across HPV16-Positive Solid Tumors
The initial development strategy is intended to support engineered TCR-T cells for HLA-A*02:01-positive patients with HPV16-positive epithelial malignancies.
Potential disease areas include cervical, oropharyngeal and other head-and-neck, anal, vulvar, vaginal and penile cancers where HPV16 is an oncogenic driver, subject to confirmation of tumor HPV16 status, HLA genotype and other clinical eligibility criteria. Current and prior clinical programs targeting HPV16 E7 have enrolled across several of these HPV-associated cancer types.
If the receptor satisfies the company’s functional and safety criteria, Cellantra also intends to evaluate compatibility with regulated receptor expression, persistence tuning, safety switches and combination strategies designed to address the immunosuppressive solid-tumor microenvironment.
Longer-term evaluation may include targeted in vivo gene-delivery systems capable of programming therapeutic T cells directly inside the body. Such applications remain exploratory.
Advancing Specificity, Safety and Resistance Testing
Cellantra will next focus on orthogonal confirmation of peptide-HLA recognition, functional T-cell activation, killing of HPV16-positive tumor targets, sparing of target-negative controls, antigen-density response and comprehensive off-target assessment.
The development program will also evaluate mechanisms that could limit activity, including reduced HLA-A*02:01 expression, defects in antigen processing and presentation, tumor heterogeneity and other forms of immune escape.
Published clinical experience with HPV16 E7 TCR-T therapy has identified defects affecting HLA-A*02:01 or antigen-presentation machinery in resistant tumors, supporting the importance of incorporating antigen-presentation escape into development strategy.
The company intends to use these studies to determine whether the lead candidate meets internal criteria for broader preclinical development, including disease-relevant tumor models, manufacturability, safety assessment and integration with its engineered-cell and future in vivo gene-therapy platforms.
The HPV16 E7/HLA-A*02:01 TCR-T candidate is investigational and has not been approved for therapeutic use. Its clinical safety and efficacy have not been established. Treatment eligibility would require confirmation of HPV16-positive disease and the appropriate HLA genotype, and no statement in this release should be interpreted as evidence of clinical benefit from Cellantra’s candidate.
About Cellantra
Cellantra is a biotechnology company developing next-generation in vivo gene therapy and precision immuno-oncology technologies. The company is building a pipeline spanning engineered T-cell receptor programs, intracellular and peptide-HLA cancer targets, in vivo immune-cell programming and advanced nucleic-acid delivery technologies.
Cellantra’s research strategy combines computational molecular design, target discovery, protein engineering, targeted delivery and experimental validation with the long-term objective of transforming complex biological discoveries into programmable therapeutic modalities.
Cellantra – Make the World a Better Place.
Forward-Looking Statements
This press release contains forward-looking statements regarding Cellantra’s HPV16 E7/HLA-A*02:01 TCR-T program, research programs, technology platforms, intellectual-property strategy, development plans and potential therapeutic applications. These statements involve scientific, technical, manufacturing, regulatory and development uncertainties. Discovery-stage characterization and preclinical findings may not predict subsequent clinical outcomes. TCR-T therapies can present risks including insufficient target recognition, HLA restriction, immune escape, unintended peptide cross-reactivity, off-target toxicity and manufacturing or persistence limitations. Cellantra’s investigational programs have not been demonstrated to be safe or effective in humans, and no assurance can be given that any program will successfully advance into or through clinical development.
